Development and Content Validity of the Statin Experience Assessment Questionnaire (SEAQ)©

Terry A. Jacobson (), Steven V. Edelman, Nina Galipeau, Alan L. Shields, Usha G. Mallya, Andrew Koren and Michael H. Davidson
Additional contact information
Terry A. Jacobson: Lipid Clinic and Cardiovascular Risk Reduction Program
Steven V. Edelman: University of California San Diego School of Medicine, Veterans Affairs Medical Center
Nina Galipeau: Adelphi Values
Alan L. Shields: Adelphi Values
Usha G. Mallya: Sanofi US
Andrew Koren: Sanofi US
Michael H. Davidson: University of Chicago Pritzker School of Medicine

The Patient: Patient-Centered Outcomes Research, 2017, vol. 10, issue 3, No 8, 334 pages

Abstract: Abstract Introduction The National Lipid Association Statin Intolerance (SI) Panel recognized the need for better understanding of the patient SI experience. Objective The objective of this research was to develop a patient-reported outcome (PRO) questionnaire to assess a patient’s experience with SI. Methods Questionnaire development was informed via a series of research activities: literature review, concept elicitation, item generation, and content evaluation. Following the literature review and concept elicitation, a draft questionnaire was constructed and subsequently modified based on feedback from therapeutic area experts and patients via cognitive debriefing interviews. Results Muscle-related symptoms were the most commonly reported symptoms associated with SI in the literature review (35 of 41 articles reviewed [85%]) and in semi-structured interviews with experts (n = 5 [100%]) and patients (n = 17 of 20 [85.0%]). Physical and other impacts of SI symptoms on daily activities were also frequently reported. A 17-item draft questionnaire was created, and cognitive debriefing with experts (n = 5) and patients (n = 15) was conducted. Overall, the items, response options, and instructions were comprehensible and positively reviewed; minor changes resulted in the 15-item Statin Experience Assessment Questionnaire (SEAQ)©. Using a 30-day recall period, the SEAQ© assesses the severity and impact of six SI symptoms (muscle ache, muscle pain, muscle cramps, muscle weakness, tiredness, and joint pain) on an 11-point numeric scale. Statin discontinuation and likelihood of discontinuation due to symptoms are assessed and scored on a yes/no and five-point verbal response scale, respectively. Conclusion The SEAQ© is a novel content-valid PRO questionnaire that assesses patient SI experience and fosters dialogue about SI between patients and providers.

Keywords: Statin; Ezetimibe; Concept Selection; Symptom Severity Scale; Statin Intolerance (search for similar items in EconPapers)
Date: 2017
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s40271-016-0211-y Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:patien:v:10:y:2017:i:3:d:10.1007_s40271-016-0211-y

Ordering information: This journal article can be ordered from
http://www.springer.com/economics/journal/40271

DOI: 10.1007/s40271-016-0211-y

Access Statistics for this article

The Patient: Patient-Centered Outcomes Research is currently edited by Christopher I. Carswell

More articles in The Patient: Patient-Centered Outcomes Research from Springer, International Academy of Health Preference Research
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().